- Joined
- 28 May 2020
- Posts
- 6,295
- Reactions
- 11,928
Israel has gone into a fourth Jab of anit virus Vax in recent times, but the latest results suggest that the fourth Jab does not provide much at all. Israel has had half a million of its citizens onto a fourth injection, but still the virus runs rampant.
FromTodays Australian
FromTodays Australian
MickIsrael experienced its highest daily number of new Covid cases this week – 71,000 out of a population of 9 million – but the head of country’s health department, Nahman Ash, concedes the number may be up to three times higher. Whichever figure is correct, the trend is certain: case numbers have been rising every day for the past two weeks, as the Omicron wave surges.
“Ninety-eight per cent of our patients are now infected with Omicron,” says Dror Mevorach, who heads the Covid ward at Hadassah hospital in Jerusalem.
From the start, Israel has been proactive, pioneering mass vaccinations and the third booster shot. Once it became clear that the largest numbers of vaccinated people contracting the Omicron variant were older, Israel last month initiated a fourth vaccine booster for those over 60, as well as frontline medical workers and the immuno-compromised.
As a fourth shot had not been approved by US regulatory authorities, the Sheba Medical Centre near Tel Aviv began a trial, testing its effect on its staff, who have been monitored since December 2020, when they received the first dose of the vaccine. Preliminary results released this week have found only middling results.
“The vaccine, which was very effective against the previous strains, is less effective against Omicron,” said Gili Regev-Yochay, who is leading the trial.
“We see many who receive the fourth dose and are infected with Omicron. Granted, a bit less than in the control group, but there are still a lot of infections. The bottom line is that the vaccine was excellent against the Alpha and Delta variants, but for Omicron it’s not good enough.”
The trial, which follows 150 medical staff, is much smaller than most drug trials, where thousands of participants are tracked for months. But Dr Regev-Yochay says she released the preliminary findings because it’s the only known study of the fourth dose. She added it was still probably beneficial to give a fourth jab to people in higher risk groups including the very elderly, but hinted that perhaps it need not be given to everyone over 60.
More than 500,000 Israelis have received a fourth dose, and Dr Alroy-Preis says with hindsight it was still the right decision. “A five to six fold increase in antibodies is better than nothing and this is the most vulnerable section of the community,” she said.